← Back to Search

Other

Gemfibrozil effet on camlipixant pharmacokinetics for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bellus Health Inc. - a GSK company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre dose to up to 72 hours post-dose
Awards & highlights
No Placebo-Only Group

Summary

This trial tests how safe a drug is by studying how it interacts with existing drugs in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre dose to up to 72 hours post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre dose to up to 72 hours post-dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measurement of the area under the plasma concentration by time curve (AUC0-inf)
Measurement of the area under the plasma concentration by time curve (AUC0-t)
Measurement of the maximum observed plasma drug concentration (Cmax)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Gemfibrozil effet on camlipixant pharmacokineticsExperimental Treatment1 Intervention
Group II: Camlipixant effect on dabigatran etexilate pharmacokineticsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dabigatran etexilate + camlipixant
2023
Completed Phase 1
~40
Camlipixant + Gemfibrozil
2023
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bellus Health Inc. - a GSK companyLead Sponsor
18 Previous Clinical Trials
5,302 Total Patients Enrolled
Bellus Health IncLead Sponsor
15 Previous Clinical Trials
5,222 Total Patients Enrolled

Media Library

Camlipixant + Gemfibrozil (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05959447 — Phase 1
Healthy Subjects Research Study Groups: Gemfibrozil effet on camlipixant pharmacokinetics, Camlipixant effect on dabigatran etexilate pharmacokinetics
Healthy Subjects Clinical Trial 2023: Camlipixant + Gemfibrozil Highlights & Side Effects. Trial Name: NCT05959447 — Phase 1
Camlipixant + Gemfibrozil (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05959447 — Phase 1
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top